Cellid Co. Ltd (KQ:299660) — Market Cap & Net Worth
Market Cap & Net Worth: Cellid Co. Ltd (299660)
Cellid Co. Ltd (KQ:299660) has a market capitalization of $52.38 Million (₩77.30 Billion) as of June 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #21790 globally and #1303 in its home market, demonstrating a 9.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cellid Co. Ltd's stock price ₩2620.00 by its total outstanding shares 29502977 (29.50 Million). Review Cellid Co. Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
Cellid Co. Ltd Market Cap History: 2019 to 2026
Cellid Co. Ltd's market capitalization history from 2019 to 2026. Data shows change from $500.15 Million to $52.38 Million (-32.47% CAGR).
Index Memberships
Cellid Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$270.08 Billion | 0.02% | #612 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$270.08 Billion | 0.02% | #612 of 1384 |
Weight: Cellid Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cellid Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cellid Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Cellid Co. Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $894.63 Million | $909.09 Million | -$13.07 Billion | 0.98x | N/A |
| 2022 | $214.09 Million | $480.00 Million | -$22.86 Billion | 0.45x | N/A |
| 2024 | $101.17 Million | $4.17 Billion | -$12.26 Billion | 0.02x | N/A |
| 2025 | $57.18 Million | $8.84 Billion | -$12.07 Billion | 0.01x | N/A |
Competitor Companies of 299660 by Market Capitalization
Companies near Cellid Co. Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Cellid Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Cellid Co. Ltd Historical Marketcap From 2019 to 2026
Between 2019 and today, Cellid Co. Ltd's market cap moved from $500.15 Million to $ 52.38 Million, with a yearly change of -32.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩52.38 Million | -8.39% |
| 2025 | ₩57.18 Million | -43.48% |
| 2024 | ₩101.17 Million | +13.20% |
| 2023 | ₩89.37 Million | -58.26% |
| 2022 | ₩214.09 Million | -76.07% |
| 2021 | ₩894.63 Million | +20.64% |
| 2020 | ₩741.58 Million | +48.27% |
| 2019 | ₩500.15 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Cellid Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $52.38 Million USD |
| MoneyControl | $52.38 Million USD |
| MarketWatch | $52.38 Million USD |
| marketcap.company | $52.38 Million USD |
| Reuters | $52.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cellid Co. Ltd
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) an… Read more